Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
112 hedge funds and large institutions have $170M invested in Insys Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 35 reducing their positions, and 25 closing their positions.
33% more call options, than puts
Call options by funds: $4.87M | Put options by funds: $3.65M
3% less capital invested
Capital invested by funds: $175M → $170M (-$4.67M)
3% less funds holding
Funds holding: 116 → 112 (-4)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
37% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$2.86M |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$1.85M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$783K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$683K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.48M |
| 3 |
FHAM
Folger Hill Asset Management
New York
|
-$3.52M |
| 4 |
SCM
Schneider Capital Management
Berwyn,
Pennsylvania
|
-$1.61M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.55M |
INSY Hedge Fund Activity: Q4 2017 in Review
112 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2017, worth a combined $170M — down 2.7% from $175M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of INSY and 22 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 22 added.
The largest buyer was Mirae Asset Global Investments, adding an estimated $2.86M. The largest seller was OrbiMed, cutting an estimated $5M.
- 112 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2017, down from 116 in Q3 2017.
- Funds reported $170M of Insys Therapeutics, Inc. stock for Q4 2017, down 2.7% quarter-over-quarter.
- 22 funds opened new Insys Therapeutics, Inc. positions in Q4 2017 and 25 closed out, a net change of -3 holders.
- The largest Insys Therapeutics, Inc. buyer in Q4 2017 was Mirae Asset Global Investments, an estimated $2.86M added.
- The largest Insys Therapeutics, Inc. seller in Q4 2017 was OrbiMed, an estimated $5M sold.
Based on aggregated 13F filings for Q4 2017.